What Are the Reasons for a False-Positive TST Result?

False-positive tuberculin skin test (TST) results occur most commonly because of prior BCG vaccination, exposure to non-tuberculous mycobacteria in the environment, or the so-called booster phenomenon triggered by repeated testing. Less often, variability in the tuberculin reagent itself or simple measurement error can push an induration reading past the positive threshold in someone who has never been infected with Mycobacterium tuberculosis. Understanding these causes matters because a false positive can lead to unnecessary chest X-rays, months of preventive antibiotic treatment, and real anxiety for the person tested.

How the TST Can Be Fooled

The TST works by injecting a small amount of purified protein derivative (PPD) just under the skin and then measuring the body’s immune reaction 48 to 72 hours later. That reaction is a delayed-type hypersensitivity response driven primarily by T cells that recognize proteins from mycobacteria and trigger localized inflammation at the injection site.¹ These T cells release signaling molecules, especially interferon-gamma and interleukin-2, which recruit more immune cells and produce the firm, raised bump (induration) that clinicians measure with a ruler.²

The vulnerability lies in what those T cells are actually recognizing. PPD is not a single molecule unique to the tuberculosis bacterium. It is a crude mixture of proteins shared, to varying degrees, across the broader mycobacterial family. So if your immune system has been primed by something other than TB, those memory T cells can still show up at the injection site and create an induration large enough to be read as “positive.” Every major cause of a false-positive TST traces back to this lack of specificity in the antigen.

BCG Vaccination

The Bacille Calmette-Guérin (BCG) vaccine is given routinely to newborns or young children in much of the world to protect against severe forms of tuberculosis. Because the vaccine uses a live, weakened strain of Mycobacterium bovis, which shares many proteins with M. tuberculosis, BCG can prime the same T cells the TST is designed to detect. This makes BCG the single most studied and most common cause of false-positive TST results globally.

How much BCG skews the test depends heavily on when the vaccine was given and how much time has passed. A large meta-analysis pooling data from over 240,000 people vaccinated as infants found that roughly 8.5% had a TST induration of 10 mm or more attributable to BCG. But among those tested ten or more years after infant vaccination, only about 1% still tested positive.³ In practical terms, if you received BCG as a baby and are now an adult, the vaccine is unlikely to be the reason for a positive TST.

The picture changes dramatically for people vaccinated after their first birthday. In those same pooled studies, about 42% of people vaccinated after infancy had a false-positive TST of 10 mm or more, and even after ten years roughly 21% still tested positive.³ A 55-year follow-up study confirmed this pattern: BCG given after infancy more than doubled the risk of TST reactivity during the first 15 years, and a modest but persistent effect lingered even decades later.⁴ One study from India found that the rate of post-vaccination TST positivity at a 10 mm cutoff was close to 58%, though this decreased at higher induration thresholds.⁵

The takeaway is that age at vaccination is a more important variable than many clinicians appreciate. A 30-year-old who was vaccinated at birth in a country with routine neonatal BCG is in a very different position from someone who received the vaccine at age seven or ten. Knowing that distinction can change how a clinician interprets a borderline positive result.

Non-Tuberculous Mycobacteria

Hundreds of species of mycobacteria live in soil, water, and dust. Most are harmless, but exposure to them can sensitize the immune system in a way that mimics a mild TB response on the TST. These organisms, collectively called non-tuberculous mycobacteria (NTM), are the second major driver of false-positive results.

A study of children with positive TST results who tested negative on a more specific blood-based test found that nearly half showed strong immune responses to M. avium, a common environmental mycobacterium, rather than to TB-specific antigens. The T-cell response to M. avium was significantly higher than the response to the TB-specific proteins ESAT-6 and CFP-10, indicating that NTM exposure, not TB infection, was behind the positive skin test.⁶ The researchers concluded that NTM sensitization in children leads to unnecessary preventive treatment and wasted resources investigating nonexistent TB exposures.

The prevalence of NTM-related false positives varies enormously by geography. Surveys conducted across different regions found that this “non-specific sensitivity” ranged from nearly universal in some localities to almost absent in others, and that higher environmental mycobacterial exposure made it increasingly difficult to distinguish true TB reactions from NTM-driven ones using standard tuberculin products.⁷ Warm, humid regions with abundant soil and water tend to have higher NTM exposure, which is part of the reason TST specificity varies so much across countries. If you live in a tropical or subtropical area and have never had TB, there’s a real chance your positive skin test reflects years of low-level environmental mycobacterial contact.

The Booster Phenomenon

This one catches people off guard because it can make a TST look like a new infection when nothing new has happened. The booster phenomenon occurs during serial testing, typically when a person who had a negative TST is retested weeks or months later and now tests positive. The first injection of tuberculin “reminds” the immune system of a prior mycobacterial exposure, whether from old TB, BCG, or NTM. By the second test, the immune response is now primed enough to cross the positive threshold.

In a study of young adults undergoing two-step tuberculin testing, researchers found that booster reactions due to actual past TB infection were uncommon and could not be reliably distinguished from false-positive reactions caused by prior BCG vaccination or NTM exposure.⁸ This is a real problem in settings where annual TST screening is required, such as healthcare workplaces. A healthcare worker who was negative last year and positive this year may not have been recently exposed to TB at all; the previous test may simply have woken up a fading memory of BCG or environmental mycobacteria.

Two-step testing protocols were developed specifically to manage this issue. The idea is to give two TSTs a week or two apart at the start of employment, so that any boosting happens on the baseline record rather than being mistaken for a conversion at the next annual screening. But even with two-step testing, distinguishing a genuine new infection from a boosted old reaction remains one of the harder clinical judgment calls in occupational health.

Variability in the Tuberculin Reagent

Not all tuberculin is created equal, and this is an underappreciated contributor to inconsistent results. PPD is produced by growing mycobacteria in liquid culture, filtering out the bacteria, and then precipitating the proteins. The specific culture medium used, the precipitation method, and the mycobacterial strain can all influence which proteins end up in the final product and how immunologically active they are.

Research comparing different brands of PPD has shown that differences in manufacturing methods lead to measurably different protein profiles in the final reagent. For instance, some producers use ammonium sulfate precipitation, which tends to recover smaller proteins, while others use trichloroacetic acid precipitation, which captures a wider range of molecular weights but can partially alter the proteins in the process. These differences affect how strongly the reagent stimulates T cells and can shift induration sizes one way or another.⁹ Although international standards exist for PPD production, they do not mandate a specific culture medium, leaving room for batch-to-batch and brand-to-brand variation that the clinician reading your forearm knows nothing about.

This means a borderline result of, say, 10 or 11 mm could potentially have been 8 or 9 mm with a different lot of tuberculin. It is not the most common cause of a false positive, but it adds another layer of noise to a test already struggling with specificity.

Measurement and Technique Errors

The TST is one of the few medical tests where the final result depends on a human being pressing a pen against someone’s forearm and measuring a bump with a ruler. That introduces real variability. The induration, not the redness, is what counts, but redness is visually dominant and can mislead inexperienced readers into overestimating the reaction. Reading the test too early (before 48 hours) or too late (after 72 hours) can also shift the result. And inter-reader variability is well documented: two trained nurses measuring the same arm can easily disagree by several millimeters, which is enough to push a borderline result across the positive threshold.

Injection technique matters too. The standard Mantoux method calls for a strictly intradermal injection, placing the tuberculin just under the top layer of skin to form a visible bleb. If the injection goes too deep (subcutaneous rather than intradermal), the antigen disperses differently and the resulting reaction can be harder to interpret. If too little tuberculin is injected because some leaked out, the test may read falsely negative; if the reading conflates a bruise or local irritation with genuine induration, the test may read falsely positive.

Efforts to reduce this human variability have included experimental smartphone-based tools that photograph the injection site and use algorithms to measure the induration in three dimensions. Early proof-of-concept work found that such digital measurement had much lower variability than the traditional ruler-and-pen method, with a standard deviation of about 0.3 mm compared to roughly 1.1 mm for manual reading.¹⁰ These technologies are not yet in widespread clinical use, but they point to one way of tightening up a test whose accuracy still depends partly on who holds the ruler.

Why Cutoff Thresholds Exist and How They Shift the Odds

The TST does not produce a simple positive or negative. It produces a number in millimeters, and the threshold for calling it “positive” depends on the person’s risk profile. In the United States, for example, most guidelines use three cutoff levels: 5 mm for people at highest risk (such as those with HIV or recent close contact with an active TB case), 10 mm for people with moderate risk factors (such as recent immigrants from high-prevalence countries, healthcare workers, or people who inject drugs), and 15 mm for people with no known risk factors.

This tiered system exists precisely because false positives are so common in lower-risk groups. Raising the threshold from 10 to 15 mm screens out a large chunk of BCG-related and NTM-related reactions. One study found that the rate of BCG-attributable false positives dropped from about 58% at the 10 mm cutoff to 34% at 15 mm.⁵ The trade-off, of course, is that a higher threshold also misses more true infections. This is the central tension of TST interpretation: specificity and sensitivity pull in opposite directions, and clinicians adjust the dial based on how much risk a missed diagnosis would carry for that particular person.

If you have been told your TST is positive and you have no risk factors, it is worth asking which cutoff was applied. A 12 mm induration in someone with no TB exposure history, no immunocompromise, and a childhood BCG vaccination is a very different clinical picture from a 12 mm result in someone who shares a household with a person undergoing TB treatment.

When Blood Tests Help Sort Things Out

Interferon-gamma release assays (IGRAs) are blood tests that measure the immune response to proteins found specifically in M. tuberculosis and not in BCG or most NTM species. Because IGRAs use antigens like ESAT-6 and CFP-10 that are absent from BCG strains and from the majority of environmental mycobacteria, they largely sidestep the two biggest causes of false-positive TSTs.

Head-to-head comparisons in BCG-vaccinated populations have concluded that IGRAs should be the preferred test for individuals with a BCG vaccination history.¹¹ The study of children with NTM-driven false-positive TSTs discussed earlier also showed that IGRA-based testing could distinguish NTM sensitization from true TB infection, potentially sparing children from months of unnecessary medication.⁶

IGRAs are not perfect. They cost more, require a blood draw and a functioning laboratory, and have their own gray zones with indeterminate results, especially in very young children and immunocompromised individuals. But in settings where false-positive TSTs create real clinical confusion, an IGRA can function as a useful tiebreaker. Many guidelines now recommend using an IGRA to confirm a positive TST in low-risk, BCG-vaccinated individuals rather than proceeding straight to treatment.

Children and the False-Positive Problem

False positives carry particular weight in pediatric medicine. Diagnosing TB in children is already difficult because children tend to harbor fewer bacteria, produce less sputum, and present with vague symptoms that overlap with common childhood illnesses.¹² The TST often ends up carrying outsized diagnostic influence simply because microbiological confirmation is harder to obtain.

At the same time, many children in high-TB-burden countries receive BCG at birth, live in environments rich in NTM, or both. The combined effect makes false-positive TSTs especially common in the very population where accurate testing matters most. A false positive in a child can trigger not just months of preventive medication with potential side effects but also an extensive contact investigation to find the adult who supposedly exposed the child. When no such adult exists because the child was never infected, that is a significant waste of public health resources and a source of family stress.

IGRAs are increasingly used in pediatric settings, though their reliability drops in children under about two years old, where immune responses are still maturing. Newer skin tests using the same TB-specific antigens found in IGRAs (ESAT-6 and CFP-10) are being developed as alternatives that combine the convenience of a skin test with better specificity. These are already approved in some countries and are under evaluation elsewhere. Early comparisons suggest they may substantially reduce the false-positive problem in BCG-vaccinated children while remaining easier to administer than a blood draw in a squirming toddler.

What a Positive TST Does Not Tell You

Even when a TST is a true positive, meaning you genuinely have been infected with M. tuberculosis, the test does not tell you whether the infection is latent or active, how recently you were infected, or whether you are contagious. A TST also stays positive for life in most people once they have been infected, so a positive result years from now does not mean a new exposure. This is part of why serial TST screening has fallen out of favor in many healthcare settings, replaced by baseline testing with IGRA confirmation when needed.

If you receive a positive TST and your clinician suspects a false positive, the usual next steps include an IGRA, a chest X-ray, and a detailed history covering BCG vaccination, country of origin, travel, and known TB contacts. No single piece of that puzzle is definitive on its own, but together they usually clarify whether treatment is warranted. The key thing is to ask questions rather than accept a positive TST at face value, especially if you were BCG-vaccinated, have no TB exposure history, and live in a low-prevalence country. The test is a screening tool with known blind spots, and your clinician should be willing to walk through the reasoning with you.